Supernus Pharmaceuticals/$SUPN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Ticker

$SUPN
Sector
Primary listing

Employees

674

SUPN Metrics

BasicAdvanced
$2.5B
39.71
$1.14
0.74
-

What the Analysts think about SUPN

Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.

Bulls say / Bears say

Acquiring Sage Therapeutics for up to $795 million brings ZURZUVAE®, the first FDA-approved oral therapy for postpartum depression, expanding Supernus's portfolio—with the transaction expected to add to earnings from 2026 and deliver up to $200 million in annual cost synergies.
The FDA approval of Onapgo™, a new apomorphine infusion device for Parkinson’s disease ‘off episodes,’ addresses a significant unmet need and is forecasted to reach U.S. peak sales of $200–300 million, strengthening Supernus’s growth outlook.
A persistent shortage of ADHD drugs over the past two years has restricted supply of existing stimulants and increased demand for branded treatments like Qelbree, supporting its growing market share and sales.
The Sage acquisition includes up to $3.50 per share in contingent milestone payments tied to ZURZUVAE’s net sales and Japanese regulatory approval, which may create additional future cash obligations for Supernus and comes with uncertainty about whether these milestones will be achieved.
Onapgo’s FDA approval followed previous rejections in 2022 and 2024, highlighting the risk of execution and the potential for further regulatory setbacks for future pipeline products.
ZURZUVAE earned only $13.8 million in U.S. net sales in Q1 2025, of which Supernus will report just half as collaboration income, suggesting the immediate financial impact to the top line may be limited.
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

SUPN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SUPN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SUPN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs